

Intervacc appoints Emma Hartman as Global Product Manager for Strangvac

Stockholm, November 25, 2020 – The animal health group Intervacc AB (publ) has appointed Emma Hartman in the role of global product manager for Strangvac, a vaccine that is expected to become a game-changer in the fight against the global equine disease strangles. Emma Hartman has a DVM degree and most recently comes from MSD Animal Health, where she held the position of Nordic product manager for equine and ruminant products.

“Emma brings extensive knowledge of vaccines and animal health products to Intervacc and will play a vital role in the success of Strangvac. In recent years, she has worked with education, sales, and marketing of veterinary pharmaceuticals at one of the world-leading, global animal health companies. In particular, she has worked with one of the leading vaccines against equine influenza. She has a passionate interest in horse welfare, and it will be fantastic to work with Emma on the launch of Strangvac”, says Andreas Andersson, CEO of Intervacc.

Intervacc develops vaccines which aim to improve animal health. Earlier this year the company submitted its application for the granting of a Community marketing authorization for Strangvac to the European Medicines Agency (EMA). Equine strangles, caused by the bacterium *Streptococcus equi*, is the most common infectious disease of horses worldwide. The disease is characterized by the formation of abscesses in the head and neck of horses, which can literally strangle the horse to death. The strangles bacteria can also hide in apparently healthy recovered horses, called carriers, which enable it to persist and spread to new premises. Outbreaks of strangles can take a long time to resolve, requiring the implementation of many measures to limit the spread of infection and ultimately, eradicate the disease from an affected stable. Therefore, strangles is a priority animal health issue among the world's equine veterinarians.

“I am really delighted to be joining Intervacc to work on the global launch of Strangvac” says Emma Hartman, *“the recombinant fusion protein technology that is used within Strangvac can finally break the cycle of S. equi infection and I am thrilled by this opportunity to provide a vaccine that will be of enormous benefit to horse owners and their horses throughout the world.”*

For more information please contact:

Andreas Andersson, CEO

Phone: +46 (0)8 120 10 601, Cell: +46 (0)73 335 99 70

E-mail: andreas.andersson@intervacc.com

The information was submitted for publication, through the agency of the contact person set out above on November 25, 2020, 08.30 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska

Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, adviser@eminova.se, +46 (0)8–684 211 10 as Certified Adviser.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 – 684 211 10

Date Created

2020-11-25